Abstract
Background: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-Kinase (PI3K)/AKT signalling pathway with a central role in the control of cell growth, survival and angiogenesis. Multiple and frequent dysregulations of this pathway in human tumors make it a central target in the development of new anticancer treatments.
Objective: To review the most significant data on mTOR pathway, role of mTOR inhibitors in cancer treatment, preclinical and clinical data of the three first generation mTOR inhibitors (temsirolimus, everolimus and deferolimus), rationales, preclinical and clinical data of second generation mTOR inhibitors.
Methods: Review of published literature on mTOR and related pathways, rapalogs and novel mTOR inhibitors.
Results/conclusions: Temsirolimus and everolimus have been approved for the treatment of metastatic Renal Cell Carcinoma (RCC), temsirolimus also for Mantle Cell Lymphoma (MCL) and everolimus will be approved for pancreatic neuroendocrine tumors; all three rapalogs are currently evaluated in phase III studies in several tumors. Only limited published data are available on new mTOR inhibitors; however, in vitro and in vivo in preclinical studies they have shown a significant antiproliferative activity against a broad panel of tumors and a favourable safety profile, with disease stabilization or even tumor regression, either as single agent or in combination.
Keywords: Mammalian target of rapamycin, temsirolimus, everolimus, deforolimus, renal cell carcinoma, mantle cell lymphoma, mTORC1/mTORC2-inhibitors, dual-kinase PI3K/mTOR-Inhibitors, tumor regression, receptor tyrosine kinases (RTKs)
Current Pharmaceutical Design
Title:Targeting mTOR Pathways in Human Malignancies
Volume: 18 Issue: 19
Author(s): Angelica Fasolo and Cristiana Sessa
Affiliation:
Keywords: Mammalian target of rapamycin, temsirolimus, everolimus, deforolimus, renal cell carcinoma, mantle cell lymphoma, mTORC1/mTORC2-inhibitors, dual-kinase PI3K/mTOR-Inhibitors, tumor regression, receptor tyrosine kinases (RTKs)
Abstract: Background: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-Kinase (PI3K)/AKT signalling pathway with a central role in the control of cell growth, survival and angiogenesis. Multiple and frequent dysregulations of this pathway in human tumors make it a central target in the development of new anticancer treatments.
Objective: To review the most significant data on mTOR pathway, role of mTOR inhibitors in cancer treatment, preclinical and clinical data of the three first generation mTOR inhibitors (temsirolimus, everolimus and deferolimus), rationales, preclinical and clinical data of second generation mTOR inhibitors.
Methods: Review of published literature on mTOR and related pathways, rapalogs and novel mTOR inhibitors.
Results/conclusions: Temsirolimus and everolimus have been approved for the treatment of metastatic Renal Cell Carcinoma (RCC), temsirolimus also for Mantle Cell Lymphoma (MCL) and everolimus will be approved for pancreatic neuroendocrine tumors; all three rapalogs are currently evaluated in phase III studies in several tumors. Only limited published data are available on new mTOR inhibitors; however, in vitro and in vivo in preclinical studies they have shown a significant antiproliferative activity against a broad panel of tumors and a favourable safety profile, with disease stabilization or even tumor regression, either as single agent or in combination.
Export Options
About this article
Cite this article as:
Fasolo Angelica and Sessa Cristiana, Targeting mTOR Pathways in Human Malignancies, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626210
DOI https://dx.doi.org/10.2174/138161212800626210 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Pertinence of Apoptosis Markers for the Improvement of In Vitro Fertilization (IVF)
Current Medicinal Chemistry The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Editorial (Hot Topic:Aspergillosis: New Insights into Disease, Diagnostic and Treatment)
Current Pharmaceutical Design Peptide Targeted Copper-64 Radiopharmaceuticals
Current Topics in Medicinal Chemistry Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences Targeting the Process of Farynesylation for Therapy of Hematologic Malignancies
Current Molecular Medicine A Hybrid Discrete Imperialist Competition Algorithm for Gene Selection for Microarray Data
Current Proteomics C-type Lectin Receptor: Old Friend and New Player
Medicinal Chemistry The S100A8 and S100A9 Proteins are Attractive Targets to Modulate Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Circulating MicroRNAs: Valuable Biomarkers for the Diagnosis and Prognosis of Gastric Cancer
Current Medicinal Chemistry Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Some 1-(Flavon-7-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-ones and Related Congeners
Letters in Organic Chemistry Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry